Mission Biocapital — 2023 Investments
1 investments dated 2023 · listed companies and verified rows first · show all
Tune Therapeuticstunetx.comin𝕏Mar 2023
Tune Therapeutics develops a therapeutic platform targeting the epigenome to treat complex diseases and regenerative medicine applications.
BiotechDeep TechHealthtechLongevityMedical DevicesDurham and Seattle, US
Akira Matsuno(Executive Officer)Derek Jantz(Executive Officer)Charles Gersbach(Director)John McHutchison(CEO, Chairman of the Board)Dan McHugh(Executive Officer, Director)Blythe Sather(Executive Officer)
Co-investorsDuke Capital PartnersNew Enterprise Associates (NEA)Hatteras Venture PartnersYosemite
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.